A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies

被引：0
|
作者：
Sessa, C.
Sharma, S. K.
Britten, C. D.
Vogelzang, N. J.
Bhalla, K. N.
Mita, M. M.
Pluard, T. J.
Stiegler, P.
Quadt, C.
Shapiro, G. I.
机构：
[1] IOSI, Bellinzona, Switzerland
[2] Nevada Canc Inst, Las Vegas, NV USA
[3] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[4] Med Coll Georgia, Augusta, GA 30912 USA
[5] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Novartis Pharmaceut, Florham Pk, NJ USA
[8] Novartis Pharmaceut, Basel, Switzerland
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3532
引用
收藏
页数：3
相关论文
共 50 条
  • [41] HSP90抑制剂AUY922与氟康唑协同抗真菌活性研究
    贾海瑞
    刘珍
    韩磊
    王苗苗
    刘伟
    陕西科技大学学报, 2021, 39 (02) : 50 - 55
  • [42] RETRACTION: Potent antitumor activity of HSP90 inhibitor AUY922 in adrenocortical carcinoma (Retraction of Vol 35, Pg 8193, 2014)
    Huang, J.
    Sun, C.
    Zhang, T.
    TUMOR BIOLOGY, 2017,
  • [43] RETRACTED: Potent antitumor activity of HSP90 inhibitor AUY922 in adrenocortical carcinoma (Retracted article. See April, 2017)
    Huang, Junchao
    Sun, Chengchao
    Zhang, Ting
    Pan, Lei
    Wang, Suqing
    He, Qiqiang
    Li, Dejia
    TUMOR BIOLOGY, 2014, 35 (08) : 8193 - 8199
  • [44] Preclinical study of HSP-90 inhibitor drug, AUY922 showed good efficacy in treatment of nasopharyngeal cancer
    Yip, Timothy T. C.
    Ngan, Roger K. C.
    Ng, Wai-Tong
    Chan, Lewis T. C.
    Tai, William C. S.
    Cheng, Wai-Wai
    Ma, Victor W. S.
    Lo, Kwok-Wai
    Li, Ya-Ping
    Yang, Michael B. H.
    Wong, Eric C. H.
    Ma, Brigette B. Y.
    Mak, Nai-Ki
    Tsao, George S. W.
    Li-Lung, Maria
    CANCER RESEARCH, 2015, 75
  • [45] Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Johnson, Melissa L.
    Yu, Helena A.
    Hart, Eric M.
    Weitner, Bing Bing
    Rademaker, Alfred W.
    Patel, Jyoti D.
    Kris, Mark G.
    Riely, Gregory J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) : 1666 - +
  • [46] Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma
    T Stühmer
    A Zöllinger
    D Siegmund
    M Chatterjee
    E Grella
    S Knop
    M Kortüm
    C Unzicker
    M R Jensen
    C Quadt
    P Chène
    J Schoepfer
    C García-Echeverría
    H Einsele
    H Wajant
    R C Bargou
    Leukemia, 2008, 22 : 1604 - 1612
  • [47] NVP-AUY922:: A novel small molecule HSP90 inhibitor with potent in vivo antitumor efficacy
    Jensen, Michael Rugaard
    Schoepfer, Joseph
    Radimersky, Thomas
    Massey, Andrew
    Brueggen, Josef
    Schweitzer, Alain
    Pfaar, Ulrike
    Ruetz, Stephan
    Guy, Chantal
    Buckler, Alan
    Schnell, Christian
    Cozens, Robert
    Brough, Paul
    Drysdale, Martin
    Quadt, Cornelia
    Garcia-Echeverria, Carlos
    Chene, Patrick
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3521S - 3521S
  • [48] Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma
    Stuehmer, T.
    Zoellinger, A.
    Siegmund, D.
    Chatterjee, M.
    Grella, E.
    Knop, S.
    Kortuem, M.
    Unzicker, C.
    Jensen, M. R.
    Quadt, C.
    Chene, P.
    Schoepfer, J.
    Garcia-Echeverria, C.
    Einsele, H.
    Wajant, H.
    Bargou, R. C.
    LEUKEMIA, 2008, 22 (08) : 1604 - 1612
  • [49] Targeting HSP90 by the Novel Inhibitor NVP-AUY922 Reduces Growth and Angiogenesis of Pancreatic Cancer
    Moser, Christian
    Lang, Sven A.
    Hackl, Christina
    Wagner, Christine
    Scheiffert, Eva
    Schlitt, Hans J.
    Geissler, Edward K.
    Stoeltzing, Oliver
    ANTICANCER RESEARCH, 2012, 32 (07) : 2551 - 2561
  • [50] NVP-AUY922, a novel HSP90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo
    Lian, Jianpo
    Lin, Dengqiang
    Xie, Xing
    Xu, Yunze
    Xu, Lieyu
    Meng, Li
    Zhu, Yu
    ONCOTARGETS AND THERAPY, 2017, 10 : 2219 - 2226
12345